drug
Lumify
Marketedupdated 3mo agoby $BLCO Bausch & Lomb Corp
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- drugCOMBIGAN37 co-mentions · 26 sources
- drugBRIMONIDINE TARTRATE33 co-mentions · 26 sources
- tagApproval32 co-mentions · 16 sources
- drugQOLIANA26 co-mentions · 19 sources
- drugbrimonidine19 co-mentions · 19 sources
- companyApotex Corp7 co-mentions · 3 sources
- tagRecall7 co-mentions · 7 sources
- drugtimolol maleate LA3 co-mentions · 3 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 9 investigational indications.
all catalysts(13)
approval · 13
May 22, 2006
approval
QOLIANA (BRIMONIDINE TARTRATE) — FDA approval
Lumify
→
Oct 30, 2007
approval
$ABBV249.46-0.54%
COMBIGAN (BRIMONIDINE TARTRATE) — FDA approval
Lumify
→
Aug 3, 2010
approval
QOLIANA (BRIMONIDINE TARTRATE) — FDA approval
Lumify
→
Mar 27, 2012
approval
QOLIANA (BRIMONIDINE TARTRATE) — FDA approval
Lumify
→
Oct 11, 2012
approval
$ABBV249.46-0.54%
COMBIGAN (BRIMONIDINE TARTRATE) — FDA approval
Lumify
→
Sep 25, 2014
approval
QOLIANA (BRIMONIDINE TARTRATE) — FDA approval
Lumify
→
Oct 15, 2015
approval
$ABBV249.46-0.54%
COMBIGAN (BRIMONIDINE TARTRATE) — FDA approval
Lumify
→
Nov 10, 2015
approval
QOLIANA (BRIMONIDINE TARTRATE) — FDA approval
Lumify
→
Jan 19, 2016
approval
QOLIANA (BRIMONIDINE TARTRATE) — FDA approval
Lumify
→
Nov 21, 2025
approval
QOLIANA (BRIMONIDINE TARTRATE) — FDA approval
Lumify
→
Mar 11, 2026
approval
BRIMONIDINE TARTRATE — FDA approval
Lumify
→
Mar 17, 2026
approval
$ABBV249.46-0.54%
COMBIGAN (BRIMONIDINE TARTRATE) — FDA approval
Lumify
→
Apr 16, 2026
approval
BRIMONIDINE TARTRATE — FDA approval
Lumify
→
Trials studying Lumify
- phase2A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
- phase3Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution
- phase3A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness
- phase3Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis
- phase3Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis
- phase2TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis
- phase3"Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness"
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 27, 2029
~2.9 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (14)
- Jun 13, 2031formulationUS 102015174.8y
- Jun 13, 2031formulationUS 80534274.8y
- Jun 13, 2031formulationUS 81637254.8y
- Mar 25, 2031formulationUS 85132474.6y
- Mar 25, 2031formulationUS 85132494.6y
- Mar 25, 2031method-of-use (U-1428)US 98616314.6y
- Mar 25, 2031method-of-use (U-1428)US 98616324.6y
- Jul 14, 2030method-of-use (U-2222)US 82937423.9y
- Jul 14, 2030method-of-use (U-2222)US 82937423.9y
- Jul 14, 2030method-of-use (U-2222)US 92594253.9y
- Jul 14, 2030method-of-use (U-2222)US 92594253.9y
- Jul 27, 2029method-of-use (U-2222)US 115966002.9y
- Jul 27, 2029method-of-use (U-2222)US 115966002.9y
- Jul 27, 2029method-of-use (U-2222)US 118332452.9y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 19m ago
Found something off?
comments(0)
5-min edit window · permanent after that